High Dose CHOP in Lymphoma

Phase 2CompletedNCT00192764

Rambam Health Care Campus45 enrolled

Overview

The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-Hodgkin's Lymphoma

Interventions

high-dose cyclophosphamideDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * large-cell non-Hodgkin's lymphoma * IPI low-intermediate, high-intermediate and high or bulky mediastinum * age 18-65 Exclusion Criteria: * previous treatment for lymphoma * serious concurrent systemic disease

Locations (1)

Department of Oncology, Rambam Medical Center

Haifa, Israel

Outcomes

Primary Outcomes

Failure-free survival

Secondary Outcomes

overall survival

response rate

toxicity

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.